arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Bionano Genomics, Inc.

BNGO
$1.10 ▼ -0.10 (-8.33%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
38 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Bionano Genomics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $12.7M
Dividend Yield —
Revenue Growth 21.4% ↗
Op. Margin -88.3% ↗
ROIC -22.9% ↘
FCF / Share $-0.40 ↗
Trailing P/E —
Price / Book 0.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

38-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.17M
↑ +21.4% —
Net Income Profit after all expenses
$-8.30M
↓ -167.7% —
Operating Margin Operating profit as % of sales
-88.3%
↑ +25.2% 2th
FCF / Share Free cash flow per share
$-0.40
↑ +22.3% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
3
Returns ↑
14
Financial Health ↑
24
Cash Quality ↓
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 38 quarters